| 1 (33) | Samsung Corp * | MUL |  |
| 2 (89) | GlaxoSmithKline * | MUL | |
| 3 (91) | AstraZeneca * | MUL | |
| 4 (122) | Sanofi * | MUL | |
| 5 (129) | F Hoffmann-La Roche * | MUL | |
| 6 (130) | Hypertension Arterielle, Pulmonaire: Physiopathologie et Innovation Therapeutique | FRA | |
| 7 (144) | GlaxoSmithKline, United Kingdom | GBR | |
| 8 (150) | Hoffmann-La Roche Ltd, United States | USA | |
| 9 (154) | Genentech Inc | USA | |
| 10 (169) | Boehringer Ingelheim * | MUL | |
| 11 (172) | Janssen | MUL | |
| 12 (179) | Boehringer Ingelheim GmbH Germany | DEU | |
| 13 (199) | Johnson & Johnson * | MUL | |
| 14 (208) | Bayer * | MUL | |
| 15 (235) | AstraZeneca, United States | USA | |
| 16 (260) | Boehringer Ingelheim, USA | USA | |
| 17 (264) | Merck * | MUL | |
| 17 (264) | Merck & Co Inc, United States | USA | |
| 19 (270) | Novartis * | MUL | |
| 20 (288) | GlaxoSmithKline, United States | USA | |
| 21 (291) | AstraZeneca, Sweden | SWE | |
| 22 (346) | AstraZeneca, United Kingdom | GBR | |
| 23 (547) | Novartis Pharmaceuticals, United States | USA | |
| 24 (580) | Novartis, Switzerland | CHE | |
| 25 (625) | Regeneron Pharmaceuticals Inc | USA | |
| 26 (743) | Medtronic * | MUL | |
| 27 (747) | Manipal Global Education Group * | MUL | |
|
